Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T17:07:50.539Z.
Calculation as of: 2026-10-06T17:07:50.539Z.
Quote observation: 2026-10-06T17:04:59.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a3d1fbdfc20658083391a22a35257b501cad1354629c31eed1b40f8a69f1a870
PE RATIO
N/A
Lucid Diagnostics Inc.
Market Cap
$114.48M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| Lucid Diagnostics Inc. (LUCD) | $114.48M | N/A |
| Genelux Corporation (GNLX)vs › | $115.46M | N/A |
| Caribou Biosciences, Inc. (CRBU)vs › | $116.34M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $116.80M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $117.76M | N/A |
| Insight Molecular Diagnostics Inc. (IMDX)vs › | $112.69M | N/A |
| MaxCyte, Inc. (MXCT)vs › | $113.01M | N/A |
| Foghorn Therapeutics Inc. (FHTX)vs › | $112.82M | N/A |
| Aardvark Therapeutics, Inc. Common Stock (AARD)vs › | $112.05M | N/A |
| BGM Group Ltd. (BGM)vs › | $111.14M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$0.60
Forward EPS (Est.)
$-0.27
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
